This trial is evaluating whether RVU120(SEL120) will improve 2 primary outcomes, 5 secondary outcomes, and 4 other outcomes in patients with Preleukemia. Measurement will happen over the course of Up to 18 months.
This trial requires 54 total participants across 1 different treatment group
This trial involves a single treatment. RVU120(SEL120) is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 1 and are in the first stage of evaluation with people.
"Around 80% of adults have at least one syndrome each year. Around 30 million adults in the United States will develop at least one syndrome a year. This makes up 13.5% of the US adult population. There is a sex bias in the prevalence of a number of syndromes. A higher prevalence is seen in people over the age of 65. A higher proportion of men have diabetes than women (17.0% versus 10.1%)." - Anonymous Online Contributor
"Symptom syndromes are terms used to describe a collection of symptoms that do not fall to the criteria of a single disease. In this case there are no obvious and well-defined criteria for the "symptom syndrome" of COPD." - Anonymous Online Contributor
"There are often multiple signs and symptoms of the syndrome, including systemic involvement in more than one system, and often a combination of the disorders mentioned in this article. Some signs and symptoms of some of the syndromes are listed above.\n\nSigns of the disorder are usually nonspecific and often the hallmark of the syndrome is the lack of a specific diagnosis.\n\nThe syndrome of systemic lupus erythematosus can be difficult to diagnose as many of the signs may be nonspecific." - Anonymous Online Contributor
"The findings reported here indicate that when all diagnostic criteria are met a significant proportion of patients with syndromic ASD, a "typical ASD syndrome" or a mixed ASD disorder can be cured with treatment. A subset of patients could achieve and maintain general health and quality of life after being successfully treated." - Anonymous Online Contributor
"Treatment is often centered on disease type, progression and severity. A wide spectrum of interventions is possible for common syndromes such as neurological and autoimmune diseases, psychiatric disorders, cardiovascular and sleep apnea." - Anonymous Online Contributor
"Syndromes are a relatively recent phenomenon. At one time they included only disorders with defined pathologies such as multiple myeloma, cerebral palsy or Huntington's disease. Today they typically include a variety of disorders associated with different genetic or metabolic abnormalities. Syndromes are a relatively recent phenomenon. At one time they included only disorders with defined pathologies such as multiple myeloma, cerebral palsy or Huntington's disease. Today they typically include a variety of disorders associated with different genetic or metabolic abnormalities. Syndromes are no more than a way to classify and label a number of disorders, although they often include a 'definite' diagnosis of a single genetic anomaly." - Anonymous Online Contributor
"In this population-based survey of treatment usage, Rvu120(sel120) typically was not used in combination with other drugs. Data from a recent study of this survey may inform future trial design for children with MELAS." - Anonymous Online Contributor
"Symptom severity varies considerably across patients and can be underestimated by clinicians or reported on by patients. Patients suffering from syndrome will generally experience much larger symptoms than patients receiving standard care in terms of physical and psychological distress, symptom severity and interference with quality of life." - Anonymous Online Contributor
"It is still not known what is the primary cause of syndrome. Our cases are probably not due to any one specific cause and instead represent cases of nonadherence to treatment. The association with autoimmune disease emphasizes the importance of early treatment in the absence of autoimmune disorders to prevent development of progressive disease." - Anonymous Online Contributor
"The patient with a specific syndrome is usually the preferred group for clinical trials. Patients who do not fit in any of the groups listed here are either too few to justify clinical trials or they are just too prevalent to justify clinical trials. Clinical trials specifically tailored to patients with a syndrome can help to show statistically significant improvement in symptoms, and it may shorten the time required for the study to answer these questions. Clinical trials that are not tailored to the specific syndrome need to be interpreted in a more circumspect manner. If the clinical trial is performed on all of the patients regardless of the condition, it takes longer, and there are more chances for the results to be meaningless." - Anonymous Online Contributor
"Although the presence or absence of the syndrome of multiple system atrophy is influenced by many different factors such as age, age of onset, sex, genetic factors and environmental factors, none of this influences the risk of developing syndrome of multiple system atrophy, meaning that the syndrome is genetically influenced." - Anonymous Online Contributor
"A small clinical study shows that rvu120(sel120) is significantly more effective than a placebo in the treatment of symptomatic hypercalcinosis. The authors conclude that rvu120(sel120) is effective in alleviating hypercalcemia, improving the quality of life of patients, and in some cases halting the progressive enlargement of calcium deposits in the body." - Anonymous Online Contributor